A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This clinical trial is evaluating a drug called MDSY-2140 in participants with hematologic malignancies and advanced solid tumors. The main goals of this study are to: * Find the recommended dose of MDSY-1240 that can be safely given to participants * Learn more about the side effects and effectiveness of MDSY-1240
Epistemonikos ID: 174586a02265d6ddcc3e247a49fac4e20c2c8cf5
First added on: Oct 28, 2026